(Q39736362)

14 September 2017

title

Effect of combination treatment of rapamycin and isoflavones on mTOR pathway in human glioblastoma (U87) cells (English)

1 reference

14 September 2017

1 reference

1 reference

Shilpa Puli

1

1 reference

14 September 2017

Aditi Jain

series ordinal

2

1 reference

14 September 2017

James C K Lai

series ordinal

3

1 reference

14 September 2017

Alok Bhushan

series ordinal

4

1 reference

14 September 2017

language of work or name

1 reference

23 February 2010

1 reference

14 September 2017

published in

Neurochemical Research

1 reference

14 September 2017

volume

35

1 reference

14 September 2017

issue

7

1 reference

14 September 2017

page(s)

986-993

1 reference

Biochemical targets of the isoflavone genistein in tumor cell lines

14 September 2017

cites work

1 reference

Crossref

https://api.crossref.org/works/10.1007%2FS11064-010-0142-2

Inhibitory effects of biochanin A on mouse lung tumor induced by benzo(a)pyrene

21 January 2018

1 reference

Crossref

https://api.crossref.org/works/10.1007%2FS11064-010-0142-2

Phase II trial of temsirolimus (CCI-779) in recurrent glioblastoma multiforme: a North Central Cancer Treatment Group Study

21 January 2018

1 reference

12 December 2020

The prognostic significance of phosphatidylinositol 3-kinase pathway activation in human gliomas

1 reference

12 December 2020

Combined inhibition of MEK and mammalian target of rapamycin abolishes phosphorylation of cyclin-dependent kinase 4 in glioblastoma cell lines and prevents their proliferation

1 reference

12 December 2020

Regulation of mTORC1 and mTORC2 complex assembly by phosphatidic acid: competition with rapamycin

1 reference

12 December 2020

The rapamycin-sensitive signal transduction pathway as a target for cancer therapy

1 reference

12 December 2020

Enhanced sensitivity of PTEN-deficient tumors to inhibition of FRAP/mTOR.

1 reference

12 December 2020

Biochanin A Modulates Cell Viability, Invasion, and Growth Promoting Signaling Pathways in HER-2-Positive Breast Cancer Cells

1 reference

12 December 2020

Inhibitors of mammalian target of rapamycin as novel antitumor agents: from bench to clinic.

1 reference

12 December 2020

Role of PI3K/AKT/mTOR signaling in the cell cycle progression of human prostate cancer

1 reference

12 December 2020

Resistance to rapamycin: a novel anticancer drug

1 reference

12 December 2020

Studies on the mechanism of resistance to rapamycin in human cancer cells

1 reference

12 December 2020

Genistein, a specific inhibitor of tyrosine-specific protein kinases

1 reference

12 December 2020

Upstream and downstream of mTOR

1 reference

12 December 2020

A pilot study of everolimus and gefitinib in the treatment of recurrent glioblastoma (GBM).

1 reference

12 December 2020

Upstream signaling inhibition enhances rapamycin effect on growth of kidney cancer cells

1 reference

12 December 2020

Inhibition of matrix degrading enzymes and invasion in human glioblastoma (U87MG) cells by isoflavones

1 reference

12 December 2020

Inhibition of Akt survival pathway by a small-molecule inhibitor in human glioblastoma

1 reference

12 December 2020

Combination therapy of inhibitors of epidermal growth factor receptor/vascular endothelial growth factor receptor 2 (AEE788) and the mammalian target of rapamycin (RAD001) offers improved glioblastoma tumor growth inhibition.

1 reference

12 December 2020

The phosphatidylinositol 3-Kinase AKT pathway in human cancer

1 reference

12 December 2020

Phosphorylation and regulation of Akt/PKB by the rictor-mTOR complex

1 reference

12 December 2020

Inhibition of glioma invasion of fetal brain aggregates.

1 reference

12 December 2020

Growth inhibition of prostate cell lines in vitro by phyto-oestrogens

1 reference

12 December 2020

Changes in tumor metabolism as readout for Mammalian target of rapamycin kinase inhibition by rapamycin in glioblastoma

1 reference

12 December 2020

Activation of Akt and eIF4E survival pathways by rapamycin-mediated mammalian target of rapamycin inhibition.

1 reference

12 December 2020

Mutations in the PI3K/PTEN/TSC2 pathway contribute to mammalian target of rapamycin activity and increased translation under hypoxic conditions

1 reference

12 December 2020

The TOR pathway: a target for cancer therapy

1 reference

12 December 2020

Mechanisms of action of rapamycin in gliomas

1 reference

12 December 2020

Mechanisms of the growth inhibitory effects of the isoflavonoid biochanin A on LNCaP cells and xenografts

1 reference

12 December 2020

Epidemiology of soy and cancer: perspectives and directions

1 reference

12 December 2020

A novel pathway regulating the mammalian target of rapamycin (mTOR) signaling

1 reference

12 December 2020

Analysis of the phosphatidylinositol 3'-kinase signaling pathway in glioblastoma patients in vivo

1 reference

12 December 2020

Mammalian target of rapamycin inhibition

1 reference

12 December 2020

Lessons learned in the development of targeted therapy for malignant gliomas.

1 reference

12 December 2020

Antitumor activity of rapamycin in a Phase I trial for patients with recurrent PTEN-deficient glioblastoma

1 reference

12 December 2020

Genetic pathways to glioblastomas

1 reference

12 December 2020

Rapamycin selectively inhibits the growth of childhood rhabdomyosarcoma cells through inhibition of signaling via the type I insulin-like growth factor receptor.

1 reference

12 December 2020

mTOR, a novel target in breast cancer: the effect of CCI-779, an mTOR inhibitor, in preclinical models of breast cancer

1 reference

12 December 2020

Biochemical correlates of mTOR inhibition by the rapamycin ester CCI-779 and tumor growth inhibition

1 reference

12 December 2020

Increased expression of the epidermal growth factor receptor gene in malignant gliomas is invariably associated with gene amplification

1 reference

12 December 2020

Mechanisms of resistance to rapamycins

1 reference

12 December 2020

Inhibition of epidermal growth factor receptor-associated tyrosine kinase blocks glioblastoma invasion of the brain

1 reference

12 December 2020

Phase 1 trial of gefitinib plus sirolimus in adults with recurrent malignant glioma

1 reference

12 December 2020

Pilot study of the combination of EGFR and mTOR inhibitors in recurrent malignant gliomas

1 reference

12 December 2020

mTORC2 activity is elevated in gliomas and promotes growth and cell motility via overexpression of rictor

1 reference

12 December 2020

Suppression of mTOR complex 2-dependent AKT phosphorylation in melanoma cells by combined treatment with rapamycin and LY294002.

1 reference

12 December 2020

Regulation of glioblastoma cell invasion by PKC iota and RhoB.

1 reference

12 December 2020

PTEN mutations in gliomas and glioneuronal tumors.

1 reference

12 December 2020

Regulation of translation initiation by FRAP/mTOR

1 reference

12 December 2020

Survival signalling by Akt and eIF4E in oncogenesis and cancer therapy

1 reference

12 December 2020

mTOR interacts with raptor to form a nutrient-sensitive complex that signals to the cell growth machinery

1 reference

12 December 2020

Genistein, a dietary-derived inhibitor of in vitro angiogenesis

1 reference

12 December 2020

Involvement of mTORC1 and mTORC2 in regulation of glioblastoma multiforme growth and motility

1 reference

12 December 2020

A rapamycin-sensitive pathway down-regulates insulin signaling via phosphorylation and proteasomal degradation of insulin receptor substrate-1.

1 reference

12 December 2020

Disruption of parallel and converging signaling pathways contributes to the synergistic antitumor effects of simultaneous mTOR and EGFR inhibition in GBM cells

1 reference

12 December 2020

Inhibition of the mammalian target of rapamycin sensitizes U87 xenografts to fractionated radiation therapy.

1 reference

12 December 2020

mTOR promotes survival and astrocytic characteristics induced by Pten/AKT signaling in glioblastoma

1 reference

12 December 2020

Phase 2 trial of erlotinib plus sirolimus in adults with recurrent glioblastoma

1 reference

12 December 2020

Dissociation of raptor from mTOR is a mechanism of rapamycin-induced inhibition of mTOR function

1 reference

12 December 2020

Advances in Molecular Therapies in Patients with Brain Tumors

1 reference

12 December 2020

Current status and challenges associated with targeting mTOR for cancer therapy

1 reference

12 December 2020

10.1007/S11064-010-0142-2

Identifiers

DOI

1 reference

14 September 2017

1 reference